Aspirin and fracture risk: a systematic review and exploratory meta-analysis of observational studies.

Anti-Inflammatory Agents, Non-Steroidal / pharmacology Aspirin / pharmacology Bone Density / drug effects Bone Density Conservation Agents / pharmacology Fractures, Bone / prevention & control Humans Risk Assessment
ageing fracture prevention general population studies osteoporosis therapeutics (other)

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 02 2020
Historique:
entrez: 23 2 2020
pubmed: 23 2 2020
medline: 16 2 2021
Statut: epublish

Résumé

This review provides insights into the potential for aspirin to preserve bone mineral density (BMD) and reduce fracture risk, building knowledge of the risk-benefit profile of aspirin. We conducted a systematic review and exploratory meta-analysis of observational studies. Electronic searches of MEDLINE and Embase, and a manual search of bibliographies was undertaken for studies published to 28 March 2018. Studies were included if: participants were men or women aged ≥18 years; the exposure of interest was aspirin; and relative risks, ORs and 95% CIs for the risk of fracture or difference (percentage or absolute) in BMD (measured by dual energy X-ray absorptiometry) between aspirin users and non-users were presented. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklists for observational studies. Pooled ORs for any fracture and standardised mean differences (SMDs) for BMD outcomes were calculated using random-effects models. Twelve studies met the inclusion criteria and were included in the meta-analysis. Aspirin use was associated with a 17% lower odds for any fracture (OR 0.83, 95% CI 0.70 to 0.99; I While the benefits of reduced fracture risk and higher BMD from aspirin use may be modest for individuals, if confirmed in prospective controlled trials, they may confer a large population benefit given the common use of aspirin in older people.

Identifiants

DOI: 10.1136/bmjopen-2018-026876 PMID: 32086348 PMC: PMC7044955
pubmed: 32086348
pii: bmjopen-2018-026876
doi: 10.1136/bmjopen-2018-026876
pmc: PMC7044955
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Bone Density Conservation Agents 0
Aspirin R16CO5Y76E

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026876

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: ALB, KS, JP, SK, PE, SAW, RGC, ES and JJM are the members of the investigator group for the ASPREE-Fracture substudy.

Références

BMC Musculoskelet Disord. 2016 May 04;17:201
pubmed: 27141945
Clin Ther. 1999 Jun;21(6):1074-90; discussion 1073
pubmed: 10440628
J Intern Med. 2006 Jul;260(1):76-87
pubmed: 16789982
Lancet. 2016 Jan 2;387(10013):61-9
pubmed: 26498706
Am J Cardiol. 2015 Apr 1;115(7):895-900
pubmed: 25670639
J Rheumatol. 1997 Jun;24(6):1132-6
pubmed: 9195522
Trends Endocrinol Metab. 2010 May;21(5):294-301
pubmed: 20079660
Psychother Psychosom. 2010;79(5):323-5
pubmed: 20689351
Stroke. 2005 Aug;36(8):1801-7
pubmed: 16020759
Bone. 2008 Sep;43(3):521-31
pubmed: 18602880
J Clin Epidemiol. 1995 Jan;48(1):109-16; discussion 117-8
pubmed: 7853037
J Bone Miner Res. 1996 Jan;11(1):29-35
pubmed: 8770694
Int J Evid Based Healthc. 2015 Sep;13(3):163-9
pubmed: 26262566
J Bone Joint Surg Am. 2009 May;91 Suppl 3:87-94
pubmed: 19411505
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
Osteoporos Int. 2012 Apr;23(4):1255-65
pubmed: 21710339
JAMA. 2006 Jan 18;295(3):306-13
pubmed: 16418466
Res Synth Methods. 2017 Sep;8(3):290-302
pubmed: 28378395
Soc Sci Med. 2000 Sep;51(6):887-95
pubmed: 10972432
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Exp Mol Pathol. 2006 Jun;80(3):219-27
pubmed: 16460728
J Bone Miner Res. 2003 Oct;18(10):1795-802
pubmed: 14584890
Lancet. 2017 Jul 29;390(10093):490-499
pubmed: 28622955
Indian J Endocrinol Metab. 2014 Jul;18(4):449-54
pubmed: 25143898
J Bone Miner Res. 1998 Dec;13(12):1924-31
pubmed: 9844111
Int J Cardiol. 2012 Sep 20;160(1):36-40
pubmed: 21463909
J Osteoporos. 2017;2017:3710959
pubmed: 28163951
BMJ. 1998 Jan 10;316(7125):140-4
pubmed: 9462324
World J Orthop. 2016 Mar 18;7(3):171-81
pubmed: 27004165
Bone. 2008 Jul;43(1):156-161
pubmed: 18448413
Lancet. 2002 Jun 1;359(9321):1929-36
pubmed: 12057569
Med Hypotheses. 2011 Mar;76(3):317-21
pubmed: 20961694
Osteoporos Int. 2015 Sep;26(9):2243-8
pubmed: 26018089
Osteoporos Int. 2006;17(9):1404-9
pubmed: 16699736
Lancet Oncol. 2009 May;10(5):501-7
pubmed: 19410194
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Osteoporos Int. 2011 Sep;22(9):2421-37
pubmed: 21110006
Calcif Tissue Int. 2006 Aug;79(2):84-94
pubmed: 16927048
Osteoporos Int. 2008 Feb;19(2):227-34
pubmed: 17874032
Osteoporos Int. 1993;3 Suppl 1:136-40
pubmed: 8461541
J Clin Endocrinol Metab. 2007 May;92(5):1678-86
pubmed: 17311861
Med J Aust. 2004 Mar 1;180(S5):S18-22
pubmed: 14984358
Int J Cardiol. 2017 Oct 1;244:298-302
pubmed: 28673738
Bone. 2011 Jun 1;48(6):1277-81
pubmed: 21396491

Auteurs

A L Barker (AL)

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia anna.barker@monash.edu.
Member Health, Medibank Private, Melbourne, Victoria, Australia.

Sze-Ee Soh (SE)

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Department of Physiotherapy, Monash University, Melbourne, Victoria, Australia.

Kerrie M Sanders (KM)

Department of Medicine-Western Health, University of Melbourne Faculty of VCA and MCM, Melbourne, Victoria, Australia.
Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne and Western Health, Melbourne, Victoria, Australia.

Julie Pasco (J)

Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Victoria, Australia.

Sundeep Khosla (S)

Division of Endocrinology and Center on Aging, Rochester, Minnesota, USA.

Peter R Ebeling (PR)

Bone and Muscle Health Research Group, School of Clinical Sciences at Monash Health, Monash Medical Centre, Melbourne, Victoria, Australia.

Stephanie A Ward (SA)

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Geeske Peeters (G)

Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.

Jason Talevski (J)

Department of Medicine-Western Health, University of Melbourne Faculty of VCA and MCM, Melbourne, Victoria, Australia.
Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne and Western Health, Melbourne, Victoria, Australia.

Robert G Cumming (RG)

School of Public Health, University of Sydney, Camperdown, New South Wales, Australia.

Ego Seeman (E)

Endocrinology and Medicine, Austin Health, Heidelberg, Victoria, Australia.
Mary McKillip Institute of Healthy Aging, Australian Catholic University, Melbourne, Victoria, Australia.

John J McNeil (JJ)

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Anti-inflammatoires non stéroïdiens › Aspirin and fracture risk: a systematic review...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Hydroxybenzoates › Salicylates › Acide acétylsalicylique › Aspirin and fracture risk: a systematic review...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Densité osseuse › Aspirin and fracture risk: a systematic review...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents de maintien de la densité osseuse › Aspirin and fracture risk: a systematic review...
questionsmedicales.fr › Plaies et blessures › Fractures osseuses › Aspirin and fracture risk: a systematic review...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Aspirin and fracture risk: a systematic review...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Aspirin and fracture risk: a systematic review...